医保D部分:通胀削减法案带来的重大变化与前行之路
2022年通胀削减法案对Part D药品福利作出重大调整,涉及受益人、联邦政府、计划赞助商和药品制造商的经济责任。变化包括对低收入补贴资格受益人新增品牌药和生物制品制造商义务;计划可能增加行政障碍,制造商可能调整患者援助计划,部分受益人因延迟参保面临罚款。提供者和政策制定者应理解变化并借助药师支持社区和团队照护以改善药物可及性。
要点
- IRA对Part D的调整涉及受益人、政府、计划赞助商和制造商的经济责任。
- 计划可能在高成本治疗前增设行政障碍,制造商可能调整患者援助计划。
- 部分依赖深度折扣药物的受益人若参保Part D将面临显著延迟参保罚款。
核心结论
- IRA对Part D的调整旨在改善药物可及并纠正财务错配,但对供应链和利益相关者行为的影响尚待观察。
研究设计与样本
- 本文为J Am Geriatr Soc发表的述评,分析2022年通胀削减法案对Part D受益结构的影响。
主要发现
- IRA新增品牌药和生物制品制造商对低收入补贴资格受益人的义务。
- 药品福利管理机构(PBM)在计划、制造商和药房之间对制造商目录价格影响大并挤压社区药房。
- 计划可能在受益人获得高成本治疗前增设更多行政障碍,制造商可能调整患者援助计划。
- 许多制造商已在安全网药房改变援助计划,依赖深度折扣药物的受益人若参保Part D将面临显著延迟参保罚款。
关键数值与推荐
- 2022年通胀削减法案引入Part D福利重大变化,涉及受益人、联邦政府、计划赞助商和药品制造商的经济义务。
临床怎么用
- 提供者和政策制定者应理解Part D变化,并借助药师技能支持社区和团队照护以改善药物可及并确保药物利大于弊。
局限性
- 对药品供应链和利益相关者行为的影响尚待观察,当前财务安排仅提示可能反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Inflation Reduction Act (IRA) of 2022 introduced major changes in the Part D benefit that aim to improve medication access and correct several of the financial misalignments in the current Part D benefit. The changes address financial obligations of Medicare beneficiaries, the federal government, Part D plan sponsors (i.e., insurance companies), and drug manufacturers. The changes include new brand and biologic manufacturer obligations to beneficiaries eligible for the low-income subsidy. Effects on the drug supply chain and stakeholder behaviors remain to be seen but current financial arrangements inform likely responses. Currently, the Pharmacy Benefit Managers (PBMs) nestled between the plans, drug manufacturers, and pharmacies heavily influence manufacturers' list prices and squeeze community pharmacies. With the IRA restructuring of Part D, plans are likely to interject more administrative obstacles before beneficiaries can obtain higher-cost therapies, while drug manufacturers might alter their patient assistance programs. Manufacturers have already begun to change their assistance programs at many safety net pharmacies. Many Medicare beneficiaries who relied on these deeply discounted medications will face significant late enrollment penalties if they do enroll in Part D plans, creating a major barrier to participation. Providers and policymakers should understand the Part D changes and leverage the skills of pharmacists to support community and team-based care that improves access to medications and ensures that medications are doing more good than harm.
引用
- Upchurch G, Saliba D. Medicare Part D: Major Shifts With the Inflation Reduction Act and a Way Forward. J Am Geriatr Soc. 2025. PMID: 39775924. doi:10.1111/jgs.19355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。